Draft:RG3487
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Oro Temp (talk | contribs) 5 months ago. (Update) |
RG3487 is a selective α7 nicotinic acetylcholine receptor partial agonist and antagonist to serotonin-3 receptors (5HT3). It demonstrated initial efficacy in a proof-of-concept phase I trial in 80 Alzheimer's patients but its development was later discontinued following the conclusion of a later phase II trial without published results.[1] A later study evaluating the effects of RG3487 on cognitive deficits associated with schizophrenia failed to find an effect, although post-hoc analysis revealed improvements in patients with high negative PANSS scores.[1]
Pharmacology
[edit]RG3487 is a combined a7 nicotinic agonist and 5HT3 antagonist, a trait it shares with tropesitron.[2]
References
[edit]- ^ a b "RG3487 | ALZFORUM". www.alzforum.org. Retrieved 2023-12-23.
- ^ Terry Jr., Alvin V.; Callahan, Patrick M.; Hernandez, Caterina M. (2015-10-15). "Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders". Biochemical Pharmacology. Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science (Satellite to the 2015 Meeting of the Society for Neuroscience) Oct 14-15, Chicago, IL USA. 97 (4): 388–398. doi:10.1016/j.bcp.2015.07.027. ISSN 0006-2952.